Does the media favor ABVX or RARE?

In the previous week, Ultragenyx Pharmaceutical had 31 more articles in the media than Abivax. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat Ultragenyx Pharmaceutical's score of 0.98 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ultragenyx Pharmaceutical 20 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or RARE?

In the previous week, Ultragenyx Pharmaceutical had 25 more articles in the media than Krystal Biotech. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.26 beat Ultragenyx Pharmaceutical's score of 0.98 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 20 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$25.72 -0.11 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$25.84 +0.12 (+0.47%)

As of 07:24 PM Eastern

Compare

RARE vs. ABVX, PRAX, PTGX, KRYS, and NUVL

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? Ultragenyx Pharmaceutical's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Protagonist Therapeutics (PTGX), Krystal Biotech (KRYS), and Nuvalent (NUVL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ultragenyx Pharmaceutical compare to Abivax?

Abivax (NASDAQ:ABVX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Abivax has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Abivax's return on equity of -99.02% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

Abivax has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 31 more articles in the media than Abivax. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat Ultragenyx Pharmaceutical's score of 0.98 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 34.74%. Ultragenyx Pharmaceutical has a consensus target price of $58.89, suggesting a potential upside of 128.96%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

Abivax has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Abivax is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Ultragenyx Pharmaceutical	$673M	3.77	-$575M	-$5.84	N/A

47.9% of Abivax shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Abivax on 10 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Praxis Precision Medicines has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Praxis Precision Medicines' return on equity of -34.15% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

In the previous week, Ultragenyx Pharmaceutical had 29 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 3 mentions for Praxis Precision Medicines. Ultragenyx Pharmaceutical's average media sentiment score of 0.98 beat Praxis Precision Medicines' score of 0.36 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,201.80	-$303.27M	-$12.93	N/A
Ultragenyx Pharmaceutical	$673M	3.77	-$575M	-$5.84	N/A

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Praxis Precision Medicines presently has a consensus target price of $585.95, indicating a potential upside of 59.21%. Ultragenyx Pharmaceutical has a consensus target price of $58.89, indicating a potential upside of 128.96%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

Summary

Praxis Precision Medicines beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Protagonist Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Protagonist Therapeutics has a net margin of 29.40% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Protagonist Therapeutics' return on equity of 12.03% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Protagonist Therapeutics	29.40%	12.03%	11.23%

In the previous week, Ultragenyx Pharmaceutical had 23 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 9 mentions for Protagonist Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.98 beat Protagonist Therapeutics' score of 0.95 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.77	-$575M	-$5.84	N/A
Protagonist Therapeutics	$46.02M	217.56	-$130.15M	$1.03	150.21

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical presently has a consensus target price of $58.89, suggesting a potential upside of 128.96%. Protagonist Therapeutics has a consensus target price of $140.53, suggesting a potential downside of 9.17%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Krystal Biotech has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.99	$204.83M	$7.98	42.82
Ultragenyx Pharmaceutical	$673M	3.77	-$575M	-$5.84	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 25 more articles in the media than Krystal Biotech. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.26 beat Ultragenyx Pharmaceutical's score of 0.98 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 54.82% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Krystal Biotech's return on equity of 19.34% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

Krystal Biotech presently has a consensus price target of $365.40, indicating a potential upside of 6.93%. Ultragenyx Pharmaceutical has a consensus price target of $58.89, indicating a potential upside of 128.96%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

Summary

Krystal Biotech beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Nuvalent has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Nuvalent is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.77	-$575M	-$5.84	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

In the previous week, Ultragenyx Pharmaceutical had 32 more articles in the media than Nuvalent. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 0 mentions for Nuvalent. Ultragenyx Pharmaceutical's average media sentiment score of 0.98 beat Nuvalent's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Ultragenyx Pharmaceutical	Positive
Nuvalent	Neutral

Nuvalent has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Nuvalent's return on equity of -40.11% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Nuvalent	N/A	-40.11%	-35.43%

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus target price of $58.89, suggesting a potential upside of 128.96%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

Ultragenyx Pharmaceutical beats Nuvalent on 11 of the 16 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.55B	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-4.40	6.91	211.91	20.71
Price / Sales	3.77	1,375.63	631.75	95.36
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	-30.99	17.26	11.18	6.40
Net Income	-$575M	-$22.72M	$3.46B	$347.95M
7 Day Performance	-1.57%	2.89%	1.98%	0.91%
1 Month Performance	-4.39%	9.74%	7.32%	5.10%
1 Year Performance	-13.63%	54.81%	24.76%	16.16%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.4211 of 5 stars	$25.72 -0.4%	$58.89 +129.0%	-13.3%	$2.55B	$673M	N/A	1,371	Analyst Forecast
ABVX Abivax	2.6767 of 5 stars	$120.73 +1.5%	$156.50 +29.6%	+48.7%	$10.38B	N/A	N/A	61	Positive News
PRAX Praxis Precision Medicines	2.9726 of 5 stars	$376.38 +2.6%	$579.55 +54.0%	+670.5%	$10.24B	$8.55M	N/A	110	Analyst Forecast
PTGX Protagonist Therapeutics	1.9926 of 5 stars	$158.62 +2.3%	$140.53 -11.4%	+168.5%	$10.04B	$281.99M	154.00	120	Analyst Upgrade
KRYS Krystal Biotech	4.1818 of 5 stars	$335.73 +1.0%	$365.40 +8.8%	+130.3%	$9.83B	$440.48M	42.07	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. ABVX, PRAX, PTGX, KRYS, and NUVL

How does Ultragenyx Pharmaceutical compare to Abivax?

Summary

How does Ultragenyx Pharmaceutical compare to Praxis Precision Medicines?

Summary

How does Ultragenyx Pharmaceutical compare to Protagonist Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Summary

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. ABVX, PRAX, PTGX, KRYS, and NUVL

How does Ultragenyx Pharmaceutical compare to Abivax?

Is ABVX or RARE more profitable?

Which has more volatility & risk, ABVX or RARE?

Does the media favor ABVX or RARE?

Do analysts rate ABVX or RARE?

Which has higher earnings & valuation, ABVX or RARE?

Do insiders and institutionals hold more shares of ABVX or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Praxis Precision Medicines?

Is PRAX or RARE more profitable?

Does the media favor PRAX or RARE?

Which has higher valuation & earnings, PRAX or RARE?

Do insiders and institutionals have more ownership in PRAX or RARE?

Which has more risk & volatility, PRAX or RARE?

Do analysts recommend PRAX or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Protagonist Therapeutics?

Is RARE or PTGX more profitable?

Does the media refer more to RARE or PTGX?

Which has stronger earnings & valuation, RARE or PTGX?

Do institutionals and insiders have more ownership in RARE or PTGX?

Do analysts recommend RARE or PTGX?

Which has more volatility and risk, RARE or PTGX?

Summary

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Which has stronger earnings & valuation, KRYS or RARE?

Do institutionals & insiders have more ownership in KRYS or RARE?

Which has more risk & volatility, KRYS or RARE?

Does the media prefer KRYS or RARE?

Is KRYS or RARE more profitable?

Do analysts recommend KRYS or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Which has preferable earnings and valuation, RARE or NUVL?

Does the media refer more to RARE or NUVL?

Is RARE or NUVL more profitable?

Do insiders & institutionals hold more shares of RARE or NUVL?

Which has more volatility & risk, RARE or NUVL?

Do analysts recommend RARE or NUVL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools